绝经雌激素治疗与乳腺癌风险
近期证据提示,子宫切除术后使用单纯雌激素治疗可降低人群风险及携带BRCA致病变异者的乳腺癌风险。
要点
- 子宫切除术后单纯雌激素治疗与乳腺癌风险降低相关
- BRCA突变者使用单纯雌激素的15年累积乳腺癌发病率低于未使用者
- 需更多数据评估雌二醇治疗对子宫切除患者的影响
核心结论
- 单纯雌激素治疗可降低子宫切除术后人群风险及BRCA致病变异携带者的乳腺癌风险。
- 需更多专门评估雌二醇治疗对子宫切除患者影响的数据。
研究设计与样本
- 10项随机试验的荟萃分析,比较雌激素治疗与安慰剂,共14,282名人群风险参与者。
- 匹配前瞻性队列研究,纳入676名BRCA突变且乳房完整的绝经激素治疗使用者。
临床怎么用
- 对有乳腺癌风险、已完成生育且计划因良性妇科疾病手术的患者,应共同决策。
- 咨询应涵盖未来乳腺癌、子宫内膜癌、心血管疾病风险及子宫切除术相关发病率。
- 适当时应告知保留子宫的替代方案。
局限性
- 需要更多专门评估雌二醇治疗对子宫切除患者影响的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent evidence suggests that use of menopausal estrogen-only therapy in patients who have undergone hysterectomy reduces breast cancer risk among patients at population risk for breast cancer as well as in those with pathogenic high-risk BRCA variants. A meta-analysis of 10 randomized trials of estrogen therapy compared with placebo among 14,282 participants at population risk noted that 3.6% those randomized to estrogen alone were diagnosed with breast cancer, compared with 4.7% of those randomized to placebo (relative risk 0.77; 95% CI, 0.65-0.91, P =.002). A matched prospective cohort study of 676 patients with BRCA mutations and intact breasts who used menopausal hormone therapy (MHT) found that the estimated 15-year cumulative incidence of breast cancer with estrogen alone compared with no MHT was 24.3%, compared with 47.3% in the matched nonusers of MHT ( P <.0001). This evidence underscores the need for more data that specifically assess the effect of estradiol therapy among patients who have undergone hysterectomy. Until such data are available, counseling patients at risk for breast cancer who have completed childbearing and are planning surgery for benign gynecologic conditions should involve shared decision-making that addresses the future risk of breast and endometrial cancers, cardiovascular disease, as well as the morbidity associated with hysterectomy. When appropriate, such counseling should also describe the availability of uterine-sparing alternatives.
引用
- Kaunitz AM, Wright JD. Menopausal Estrogen Therapy and Risk of Breast Cancer. Obstet Gynecol. 2026. PMID: 42594383. doi:10.1097/AOG.0000000000006397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。